ADVA
ADVA (FSE: ADV) today announced that Equinix – the world’s digital infrastructure company™ – has deployed ADVA’s FSP 3000 open optical transport technology to provide Antoni van Leeuwenhoek, one of the Netherland’s leading hospitals, with encrypted dark fiber and fully managed services. Linking the healthcare provider’s data centers and facilities, the solution enables Equinix Managed Services to deliver secure Ethernet services up to 40GbE and highly reliable, low-latency Fibre Channel storage area network (SAN) connectivity up to 32Gbit/s. With ADVA’s ConnectGuard™ optical encryption technology ensuring robust data protection, the solution gives the hospital access to bandwidth-hungry applications and allows patient and medical research information to be securely collected, managed, analyzed and shared.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005540/en/
“By harnessing ADVA FSP 3000 technology and the support of the ADVA and TrueCom teams, we’re enabling Antoni van Leeuwenhoek hospital to transform its operations. With high-capacity, low-latency connectivity to its data centers, all protected by robust encryption at the optical layer, the hospital’s medics and support staff can leverage new applications and collaborate like never before to advance cutting-edge research and enhance patient care,” said Art de Blaauw, director of technology and innovation, Managed Services Solutions at Equinix. “It’s crucial for the healthcare industry that patient data is secure. ADVA’s ConnectGuard™ solution safeguards the network stack without adding latency or affecting throughput. That means medical practitioners can access critical information at any time, which is crucial for efficient processes and patient outcomes.”
Built on ADVA’s FSP 3000 open optical transport solution, the new network is capable of secure high-capacity transmission of Ethernet services up to 40GbE. With its agile, scalable and modular design, the FSP 3000 provides a truly flexible foundation, ready to expand and evolve as the needs of the healthcare provider change. The solution enables a high-speed SAN capable of transporting 32Gbit/s Fibre Channel, ensuring rapid access to patient information. This is key for healthcare professionals dealing with huge data sets. The infrastructure is comprehensively secured at the physical layer by ADVA FSP 3000 ConnectGuard™ , which is easy to operate and highly efficient, delivering the lowest cost per bit of any network encryption solution available today. ADVA’s partner TrueCom also played a key role in this project, providing installation and support, ensuring the new infrastructure met all the end customer’s requirements.
“We’re proud that our solution is now helping another major healthcare provider optimize its operations. Protecting the integrity and privacy of patients’ sensitive data couldn’t be more critical. That’s why our security technology is so important here. It ensures valuable data remains safe at every stage of its journey, while data-intensive applications continue to run,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Approved by the German Federal Office for Information Security (BSI), our FSP 3000 ConnectGuard™ optical encryption ensures that patient records are protected by the most robust security methods available while adding virtually no delay.”
“There’s no doubt that the medical industry is at the forefront of the battle against cybercrime. Criminals see healthcare providers as treasure troves of valuable data that can easily be monetized. But thanks to our close collaboration with Equinix and ADVA, this hospital can be assured that its systems are secured,” said Dhieradj Ramanand, optical solutions sales manager at TrueCom. “With the ADVA FSP 3000 ConnectGuard™ optical security solution safeguarding data in motion right across the network, encrypted signals become worthless to a hacker. That’s why this technology is the last word in data security. It’s also the key to peace of mind for medical practitioners and their patients.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005540/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
